Table 3.

Subgroup analyses of rates of changes in LDL-C at 12 weeks from baseline.

Subgroups		Hybutimibe plus atorvastatin, mmol/l	Atorvastatin, mmol/l	P-value
Age	<60 yrs	−15.11 (−20.74, −9.48) (n = 38)	−7.91 (−11.90, −3.93) (n = 50)	0.0331
	≥60 yrs	−16.93 (−19.93, −13.94) (n = 90)	−5.97 (−9.73, −2.22) (n = 75)	<0.0001
Sex	Males	−16.43 (−19.67, −13.18) (n = 79)	−7.55 (−10.79, −4.30) (n = 78)	0.0002
	Females	−16.34 (−21.03, −11.65) (n = 49)	−5.42 (−10.43, −0.42) (n = 47)	0.0018
Coronary heart disease	Yes	−17.77 (−20.75, −14.78) (n = 90)	−7.12 (−10.03, −4.20) (n = 88)	<0.0001
	No	−13.14 (−18.69, −7.59) (n = 38)	−5.87 (−12.20, 0.46) (n = 37)	0.0835
Stroke	Yes	−16.05 (−21.06, −11.05) (n = 30)	−3.64 (−12.56, 5.28) (n = 21)	0.0098
	No	−16.50 (−19.65, −13.35) (n = 98)	−7.38 (−10.19, −4.57) (n = 104)	<0.0001
Diabetes	Yes	−16.10 (−19.84, −12.36) (n = 62)	−6.30 (−10.71, −1.89) (n = 55)	0.0009
	No	−16.67 (−20.52, −12.82) (n = 66)	−7.10 (−10.63, −3.58) (n = 70)	0.0004